BIIB-068

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBIIB-068
Drug Alias NameBIIB-068
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen Inc
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A